Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atypical Hyperplasia Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Molecular Breast Imaging in Women With Atypia and LCIS

NCT00620087
View directory record Official record
Conditions
Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
Interventions
Molecular Breast Imaging, Screening Mammography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Jul 21, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

NCT01372644
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast
Interventions
SOM 230 / Pasireotide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jul 21, 2026, 9:32 PM EDT
Not listed Not applicable Interventional

CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

NCT00892866
View directory record Official record
Conditions
Atypical Endometrial Hyperplasia, Human Papillomavirus Infection, Stage 0 Cervical Cancer AJCC v7
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
135
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 100 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jul 21, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy

NCT00843167
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
broccoli sprout extract, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 21, 2026, 9:32 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

NCT03671811
View directory record Official record
Conditions
Atypical Endometrial Hyperplasia, Endometrial Carcinoma
Interventions
Megestrol Acetate, Pterostilbene
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 21, 2026, 9:32 PM EDT
Completed No phase listed Observational

X-Ray Mammography Standard of Care Protocol

NCT01052740
View directory record Official record
Conditions
Breast Cancer, Invasive Carcinoma, In Situ Carcinoma, Fibrocystic Changes, Atypical Ductal Hyperplasia
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Protocol for Women at Increased Risk of Developing Breast Cancer

NCT00291694
View directory record Official record
Conditions
Breast Cancer
Interventions
celecoxib, placebo
Drug · Other
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Jul 21, 2026, 9:32 PM EDT
Not listed Phase 2 Interventional

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

NCT02335203
View directory record Official record
Conditions
Grade 1 Endometrial Endometrioid Adenocarcinoma, Grade 2 Endometrial Endometrioid Adenocarcinoma, Complex Atypical Endometrial Hyperplasia
Interventions
Depot medroxyprogesterone acetate, Placebo
Drug · Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Jul 21, 2026, 9:32 PM EDT
Recruiting Phase 2 Interventional

Uterine Preservation Via Lifestyle Transformation

NCT05903131
View directory record Official record
Conditions
Endometrial Hyperplasia, Grade 1 Endometrial Cancer
Interventions
Telemedicine behavioral weight intervention, Progestin, Enhanced usual care, Levonorgestrel-releasing IUD.
Behavioral · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
St Louis, Missouri • Albuquerque, New Mexico • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 21, 2026, 9:32 PM EDT
Completed No phase listed Observational

An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg

NCT00291109
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole 2.5 mg
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2008 · Synced Jul 21, 2026, 9:32 PM EDT
Terminated Not applicable Interventional Results available

Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia

NCT03505372
View directory record Official record
Conditions
Atypical Ductal Hyperplasia
Interventions
Contrast enhanced mammography
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
30 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jul 21, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding

NCT06365905
View directory record Official record
Conditions
Endometrial Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 21, 2026, 9:32 PM EDT
Completed Not applicable Interventional

Endometrial Cell Collection With the PadKit

NCT06464107
View directory record Official record
Conditions
Neoplasms
Interventions
PadKit™ from Preprogen
Device
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Neptune City, New Jersey • Red Bank, New Jersey
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 21, 2026, 9:32 PM EDT
Completed Not applicable Interventional

Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer

NCT01874184
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
counseling intervention, behavioral dietary intervention, exercise intervention, questionnaire administration, laboratory biomarker analysis
Other · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 65 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jul 21, 2026, 9:32 PM EDT
Not yet recruiting Phase 2 Interventional

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

NCT07349641
View directory record Official record
Conditions
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions
Medical Device Usage and Evaluation, Tirzepatide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia

NCT00596011
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Polyphenon E, Placebo
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Lakeland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Jul 21, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

NCT03323658
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Bexarotene, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Jul 21, 2026, 9:32 PM EDT
Completed No phase listed Observational

Markers for Breast Cancer

NCT00339248
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older · Female only
Enrollment
2,632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Jul 21, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

NCT05178498
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
Interventions
Follow-Up, Physical Examination, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 9:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer

NCT00291096
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Carol Fabian, MD
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1989 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 21, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

Endometrial Cancer Vaginal Fluid Specimen Collection Study

NCT07544680
View directory record Official record
Conditions
Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
Interventions
Not listed
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 9:32 PM EDT
Not yet recruiting Phase 2 Interventional

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

NCT07499999
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
Interventions
Exemestane, Tamoxifen
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 21, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate

NCT00483327
View directory record Official record
Conditions
Atypical Endometrial Hyperplasia, Endometrial Carcinoma
Interventions
Megestrol Acetate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Jul 21, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Ruxolitinib for Premalignant Breast Disease

NCT02928978
View directory record Official record
Conditions
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
Interventions
Ruxolitinib, Placebo (for Ruxolitinib)
Drug
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 9:32 PM EDT